IVANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as IVEVF

Inventiva S.A.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026

$2.98+0.04 (+1.36%)

Close on Oct 19, 2026

Inventiva S.A. income statement

AnnualQuarterlyTTM

EUR USD

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	5.06	9.95	19	13	4.96	0.42	7.83	3.77
Research & Development	98	98	119	64	57	27	38	37
Selling & Marketing	5.60	2.11	2.14	2.72	0.43	0.64	0.28	0.27
Operating Income	-159	-106	-111	-60	-62	-34	-34	-39
Interest Expense	245	96	7.44	2.21	3.12	6.79	0.09	0.30
Interest & Investment Income	4.70	3.12	1.93	5.17	6.48	2.34	0.20	0.17
Income Tax Expense	0.02	0.34	0.66	-0.02	0.43	0	0	–
Net Income incl. Noncontrolling Interests	-400	-199	-119	-57	-59	-38	-34	-39
EPS (Basic)(per share)	-2.14	-3.33	-2.63	-1.38	-1.50	-1.13	-1.43	-1.90
EPS (Diluted)(per share)	-2.14	-3.33	-2.63	-1.38	-1.50	-1.13	-1.43	-1.90
Shares Outstanding (Basic, Weighted)(shares)	187	60	45	41	39	34	24	–
Shares Outstanding (Diluted, Weighted)(shares)	187	60	45	41	39	34	24	21

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -3145.5%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 3.81
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 257.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.